di-Pal-MTO structure
|
Common Name | di-Pal-MTO | ||
---|---|---|---|---|
CAS Number | 1349197-90-5 | Molecular Weight | 917.27 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C54H84N4O8 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of di-Pal-MTOdi-Pal-MTO is a palm oil-based lipid produced by combining the anticancer drug mitoxantrone (MTO) with palmitoleic acid. When nanoparticles of mono-Pal-MTO and di-Pal-MTO are combined in a molar ratio of 1:1, they show effective siRNA cell delivery and enhance anticancer activity[1]. |
Name | di-Pal-MTO |
---|
Description | di-Pal-MTO is a palm oil-based lipid produced by combining the anticancer drug mitoxantrone (MTO) with palmitoleic acid. When nanoparticles of mono-Pal-MTO and di-Pal-MTO are combined in a molar ratio of 1:1, they show effective siRNA cell delivery and enhance anticancer activity[1]. |
---|---|
Related Catalog | |
In Vitro | Delivery of Mcl-1-specific anticancer siRNA (siMcl-1) using nanoparticles of mono-Pal-MTO and di-Pal-MTO (md11-Pal-MTO) in a 1:1 molar ratio enhances in vitro antitumour activity, reducing tumour cell viability by 81% and tumour size by 83%. Lipofectamine 2000-mediated transfection with siMcl-1 reduces tumour cell viability by 68%[1]. |
References |
Molecular Formula | C54H84N4O8 |
---|---|
Molecular Weight | 917.27 |